Cabotegravir is not associated with weight gain in human immunodeficiency virus-uninfected individuals in HPTN 077
Clinical Infectious Diseases, ISSN: 1537-6591, Vol: 70, Issue: 2, Page: 319-322
2020
- 39Citations
- 25Usage
- 70Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations39
- Citation Indexes37
- 37
- CrossRef6
- Policy Citations2
- Policy Citation2
- Usage25
- Abstract Views25
- Captures70
- Readers70
- 70
- Mentions1
- News Mentions1
- News1
Most Recent News
HIV drug cabotegravir not associated with weight gain
The novel integrase inhibitor cabotegravir — which is currently in development for both HIV prevention and treatment — was not associated with excess weight gain in HIV-uninfected patients compared with placebo, according to a recent study. “ART that contains an integrase inhibitor has been associated with weight gain and increased waist circumference, with changes of greater magnitude seen among
Article Description
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor- based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups.
Bibliographic Details
https://hsrc.himmelfarb.gwu.edu/sphhs_epibiostats_facpubs/1232; https://hsrc.himmelfarb.gwu.edu/sphhs_epibiostats_facpubs/602
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85077403115&origin=inward; http://dx.doi.org/10.1093/cid/ciz439; http://www.ncbi.nlm.nih.gov/pubmed/31125395; https://academic.oup.com/cid/article/70/2/319/5498404; https://hsrc.himmelfarb.gwu.edu/sphhs_epibiostats_facpubs/1232; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=2233&context=sphhs_epibiostats_facpubs; https://hsrc.himmelfarb.gwu.edu/sphhs_epibiostats_facpubs/602; https://hsrc.himmelfarb.gwu.edu/cgi/viewcontent.cgi?article=1603&context=sphhs_epibiostats_facpubs; https://dx.doi.org/10.1093/cid/ciz439
Oxford University Press (OUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know